Cumberland Pharmaceuticals
CPIX
21 hedge funds and large institutions have $4.17M invested in Cumberland Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 4 closing their positions.
617% more call options, than puts
Call options by funds: $86K | Put options by funds: $12K
18% more capital invested
Capital invested by funds: $3.52M → $4.17M (+$646K)
1.24% less ownership
Funds ownership: 16.6% → 15.36% (-1.2%)
9% less funds holding
Funds holding: 23 → 21 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$126K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.9K |
| 3 |
JP Morgan Chase
New York
|
+$17 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$214K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$133K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.2K |
| 5 |
Millennium Management
New York
|
-$15.3K |
CPIX Hedge Fund Activity: Q3 2023 in Review
21 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2023, worth a combined $4.17M — up 18% from $3.52M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CPIX and 2 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 2 added.
The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $126K. The largest seller was Dimensional Fund Advisors, cutting an estimated $214K.
- 21 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2023, down from 23 in Q2 2023.
- Funds reported $4.17M of Cumberland Pharmaceuticals stock for Q3 2023, up 18% quarter-over-quarter.
- 2 funds opened new Cumberland Pharmaceuticals positions in Q3 2023 and 4 closed out, a net change of -2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q3 2023 was Bank of New York Mellon, an estimated $126K added.
- The largest Cumberland Pharmaceuticals seller in Q3 2023 was Dimensional Fund Advisors, an estimated $214K sold.
Based on aggregated 13F filings for Q3 2023.